Skip to content

To evaluate the efficacy and safety of intense pulsed laser in the treatment of melasma

To evaluate the efficacy and safety of intense pulsed laser in the treatment of melasma

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098464
Enrollment
Unknown
Registered
2025-03-10
Start date
2025-03-10
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

melasma

Interventions

Treatment group:Intense pulsed light therapy

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age 18-65 years old, gender is not limited; 2. Patients diagnosed with melasma based on medical history, dermoscopy, skin confocal microscopy, and VISIA results; 3. Subjects are in good health and have no photosensitivity diseases, serious systemic diseases, immunodeficiency or autoimmunity diseases, etc.; 4. The subject has normal behavioral capacity and no history of mental illness; 5. Fully understand the content of the trial, voluntarily participate in the trial, be able to cooperate with the treatment and follow-up according to the doctor's instructions, and sign the informed Consent.

Exclusion criteria

Exclusion criteria: 1. Melasma combined with other pigmented or inflammatory skin diseases 2. Other photoelectric treatments that are in use, have been used before the start of the trial, or plan to use during the trial, including but not limited to pulsed dye laser, Q-switched 1064, picosecond 755, etc.; 3. Use of photosensitizing drugs in the past week, such as quinolone fluxacin, non-steroidal anti-inflammatory drugs aspirin, ibuprofen, retinoids isotretinoin, etc.; 4. Those who have mental disorders and cannot cooperate; 5. Those who cannot follow the doctor's instructions for sun protection after surgery. 6. Patients with severe organic diseases.

Design outcomes

Primary

MeasureTime frame
VISIA erythema score;L*a*b value;VISIA drab-colored patch score;

Countries

China

Contacts

Public ContactXiang Wen

West China Hospital, Sichuan University

xiangwen_wcums@163.com+86 189 8060 6449

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026